Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023

Abstract: The field of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rapidly evolving. Recent clinical developments in this ultra-rare hematologic malignancy have included the emergence of […]

Novel Approaches to the Treatment of Multiple Myeloma

Abstract: The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly […]

Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma

Abstract: The landscape for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) has continued to evolve. However, challenges continue to exist, […]

Management of Testicular Germ Cell Tumors

Abstract: Over the past half century, advancements in treatment have led to cures in an overwhelming majority of patients with testicular germ cell tumors. Astute clinical […]

Management of Toxicities Associated With Immune Checkpoint Inhibitors

Abstract: Immune-related adverse events (irAEs) encompass a diverse range of toxicities following treatment with immune checkpoint inhibitors (ICIs), each with distinctive symptoms, severities, and outcomes. irAEs […]

CAR T-Cell Therapy for CLL: A New Addition to Our Treatment Toolbox?

Abstract: Treatment of high-risk chronic lymphocytic leukemia (CLL) has undergone a revolution in recent years with the introduction of novel agents. Bruton kinase inhibitors (BTK) inhibitors, […]

The Emerging Use of Chemotherapy-Free Regimens in Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Abstract: Before the development of tyrosine kinase inhibitors (TKIs), the outcome of patients with a diagnosis of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia was dismal. Combinations […]

A Review of Essential Thrombocythemia and Its Complications

Abstract: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased platelet count in the peripheral blood and excessive megakaryopoiesis in the bone marrow. […]

Immunotherapy Treatment Landscape for Patients With Endometrial Cancer: Current Evidence and Future Opportunities

Abstract: Endometrial cancer is the most common gynecologic cancer in the United States, with a rising incidence and mortality. Traditionally, systemic treatment has included combination platinum- […]

Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

Abstract: Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly […]

Ongoing Progress in BRAF-Mutated Non–Small Cell Lung Cancer

Abstract: Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non–small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated […]

The Role of Cytoreductive Surgery and Intraperitoneal Chemotherapy in Gastric Cancer

Abstract: Gastric cancer (GC) with peritoneal carcinomatosis (PC) progresses rapidly and has historically dismal survival rates. Given the aggressive tumor biology and poor survival outcomes of […]

Treatment of Amyloid Light Chain Cardiac Amyloidosis: Systematic Review and Future Directions

Abstract: Background: Several treatment strategies for amyloid light chain cardiac amyloidosis (AL-CA) have been described in the literature; however, there is no consensus about the optimal […]

Current and Emerging Options for Patients With Melanoma Brain Metastases

Abstract: Melanoma is the most aggressive skin cancer, with a high incidence of metastatic spread and a predilection for metastases to the brain. It represents the […]

How We Manage Idiopathic Multicentric Castleman Disease

Overview • We recommend first-line treatment with anti–interleukin 6 (anti–IL-6) for all patients with idiopathic multicentric Castleman disease. • We recommend enrollment of all patients with […]

A Narrative Review of Anti–SARS-CoV-2 Vaccines and Immune Thrombocytopenia: Be Aware, But Reassured

Abstract: Background: The COVID-19 pandemic gave rise to rapid development of anti–SARS-CoV-2 vaccines using established and new technologies. Immune thrombocytopenia (ITP) is a bleeding disorder that […]

Hematologic Concerns in Transgender Patients

Abstract: Patients with gender dysphoria are increasingly seeking gender-affirming therapies, which can have adverse hematologic effects. For example, estrogen can increase the risk for arterial and […]

New Treatment Strategies for Waldenström Macroglobulinemia

Abstract: The development of high-throughput technologies has allowed us to characterize the molecular landscape of hematologic neoplasms and identify somatic mutations. As a result, we can […]

JAK Inhibitors in the Treatment of Myelofibrosis

Abstract: Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary […]

The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies

Abstract: The analysis of circulating tumor DNA (ctDNA) has multiple uses in oncology. In the past few years, studies with varying designs, methods, and quality have […]